Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials

被引：36

作者：

Collette, Laurence ^{[1
]}

机构：

[1] European Org Res Treatment Canc, Ctr Data, Dept Stat, B-1200 Brussels, Belgium

来源：

EUROPEAN UROLOGY | 2008年 / 53卷 / 01期

关键词：

D O I：

10.1016/j.eururo.2007.08.041

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

收藏

页码：6 / 9

页数：4

相关论文

共 12 条

[1]

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators [J].

Beer, Tomasz M. ;

Ryan, Christopher W. ;

Venner, Peter M. ;

Petrylak, Daniel P. ;

Chatta, Gurkamal S. ;

Ruether, J. Dean ;

Redfern, Charles H. ;

Fehrenbacher, Louis ;

Saleh, Mansoor N. ;

Waterhouse, David M. ;

Carducci, Michael A. ;

Vicario, Daniel ;

Dreicer, Robert ;

Higano, Celestia S. ;

Ahmann, Frederick R. ;

Chi, Kim N. ;

Henner, W. David ;

Arroyo, Alan ;

Clow, Fong W. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) :669-674

[2]

Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49

[3]

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?: Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals [J].

Collette, L ;

Burzykowski, T ;

Carroll, KJ ;

Newling, D ;

Morris, T ;

Schröder, FH .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6139-6148

[4]

Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer [J].

D'Amico, AV ;

Moul, J ;

Carroll, PR ;

Sun, L ;

Lubeck, D ;

Chen, MH .

JOURNAL OF UROLOGY, 2005, 173 (05) :1572-1576

[5]

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy [J].

D'Amico, AV ;

Moul, JW ;

Carroll, PR ;

Sun, L ;

Lubeck, D ;

Chen, MH .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1376-1383

[6]

End points and United States food and drug administration approval of oncology drugs [J].

Johnson, JR ;

Williams, G ;

Pazdur, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1404-1411

[7]

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells [J].

Lin, Amy M. ;

Hershberg, Robert M. ;

Small, Eric J. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (05) :434-441

[8]

Newling D, 2004, J CLIN ONCOL, V22, p419S

[9]

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 [J].

Petrylak, DP ;

Ankerst, DP ;

Jiang, CS ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (08) :516-521

[10]

SANDLER HM, 2003, J CLIN ONCOL, V22, P381